Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189619 | 0.80 | SIGMAR1 (0.47) | SLC6A4SLC6A2SIGMAR1CYP2C19TDP1 | |
| SCHEMBL6008596 | 0.78 | SIGMAR1 (0.45) | SLC6A4SLC6A2SIGMAR1CYP2C19TDP1 | |
| SCHEMBL26893117 | 0.77 | SIGMAR1 (0.47) | SLC6A4SLC6A2SIGMAR1CYP2C19ALDH1A1 | |
| SCHEMBL19486854 | 0.77 | SIGMAR1 (0.47) | SLC6A4SLC6A2SIGMAR1CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6335769 | 0.76 | KDM4E (0.39) | SLC6A4SLC6A2ALDH1A1TDP1 | |
| SCHEMBL16757387 | 0.76 | TDP1 (0.42) | SLC6A4SLC6A2CYP2C19ALDH1A1TACR1 | |
| Hydrochloric Acid SCHEMBL8693217 | 0.74 | TDP1 (0.43) | SLC6A4SLC6A2SIGMAR1CYP2C19ALDH1A1 | |
| SCHEMBL16757280 | 0.74 | TDP1 (0.46) | SLC6A4SLC6A2CYP2C19ALDH1A1TACR1 | |
| SCHEMBL5683230 | 0.74 | TDP1 (0.41) | SLC6A4SLC6A2CYP2C19TACR1TDP1 | |
| SCHEMBL7337323 | 0.74 | TDP1 (0.42) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997023466-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1997-07-03 | — | — | WO | claimed |
| US-20040138228-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-07-15 | — | — | US | disclosed |
| WO-1997023466-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | SLC6A4 1098/4885SLC6A2 1081/4885SIGMAR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.